Present and future breast cancer management-bench to bedside and back: A positioning paper of academia, regulatory authorities and pharmaceutical industry

R. Bartsch, S. Frings, M. Marty, A. Awada, A. S. Berghoff, P. Conte, S. Dickin, H. Enzmann, M. Gnant, M. Hasmann, H. R. Hendriks, A. Llombart, C. Massacesi, G. Von minckwitz, F. Penault-llorca, M. Scaltriti., Y. Yarden, H. Zwierzina, C. C. Zielinski

Research output: Contribution to journalArticle

Abstract

Insights into tumour biology of breast cancer have led the path towards the introduction of targeted treatment approaches; still, breast cancer-related mortality remains relatively high. Efforts in the field of basic research revealed new druggable targets which now await validation within the context of clinical trials. Therefore, questions concerning the optimal design of future studies are becoming even more pertinent. Aspects such as the ideal end point, availability of predictive markers to identify the optimal cohort for drug testing, or potential mechanisms of resistance need to be resolved. An expert panel representing the academic community, the pharmaceutical industry, as well as European Regulatory Authorities met in Vienna, Austria, in November 2012, in order to discuss breast cancer biology, identification of novel biological targets and optimal drug development with the aim of treatment individualization. This article summarizes statements and perspectives provided by the meeting participants.

Original languageEnglish
Article numbermdt531
Pages (from-to)773-780
Number of pages8
JournalAnnals of Oncology
Volume25
Issue number4
DOIs
Publication statusPublished - 2014

Keywords

  • Biological subtypes
  • Breast cancer
  • HER2-positive disease
  • Luminal disease
  • Triple-negative disease

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Present and future breast cancer management-bench to bedside and back: A positioning paper of academia, regulatory authorities and pharmaceutical industry'. Together they form a unique fingerprint.

  • Cite this

    Bartsch, R., Frings, S., Marty, M., Awada, A., Berghoff, A. S., Conte, P., Dickin, S., Enzmann, H., Gnant, M., Hasmann, M., Hendriks, H. R., Llombart, A., Massacesi, C., Von minckwitz, G., Penault-llorca, F., Scaltriti., M., Yarden, Y., Zwierzina, H., & Zielinski, C. C. (2014). Present and future breast cancer management-bench to bedside and back: A positioning paper of academia, regulatory authorities and pharmaceutical industry. Annals of Oncology, 25(4), 773-780. [mdt531]. https://doi.org/10.1093/annonc/mdt531